SMU-R39

SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. It binds to recombinant mTLR7 protein (KD= 2.36 μM) and recombinant hTLR8 protein (KD= 105 nM) . SMU-R39 inhibits downstream NF-κB and MAPK signaling pathways, reducing the secretion and transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. In an Imiquimod (IMQ) -induced psoriasis mouse model, SMU-R39 exhibits anti-inflammatory activity and may be used for researching autoimmune diseases such as psoriasis.